Patrick Frayssinet

World Vaccine Congress Washington Speaker Interview: Dr Patrick Frayssinet

|| Dr Patrick Frayssinet, R&D Director, URODELIA We have interviewed a few of the speakers from World Vaccine Congress Washington, taking place on 10-12 April 2017 in Grand Hyatt Washington. This is the 1st of the interview series, stay connected for more. Q1: The most promise opportunities in the veterinary vaccines space are? A: One of the most promise opportunities …

World Vaccine Congress Washington, April 7-9 2015

Download eBook: Discussion topics from Pandemic Influenza, 2nd Edition

Pandemic influenza is a re-emerging disease with serious public health consequences. The H1N1 pandemic in 2009-10 and the continuing threat to humans from avian influenza H5N1 and H5N8 have underlined this threat. Particularly in an increasingly globalised society, it is essential that we have preparedness plans in please at a local, national and international level. Download this eBook to: Gain …

ViroCyt white paper: Exhibitors of the World Vaccine Congress, Washington, 2015

Guest blog: ViroCyt ‘Virotherapy Process Optimization’ white paper

An emerging application of viruses involves engineering them to treat diseases using a number of approaches. Broadly defined under the “Virotherapy” umbrella, these include viral vectors used for gene therapy, oncolytic viruses and viral immunotherapy. A significant challenge, as it is for any virus-based technology, is gaining a clear picture of the quality of a sample at any given point: …

World Vaccine Congress Washington 2015

Download: ‘Vaccine Insights’ eBook, interviews with the leaders of the vaccine industry

The world of vaccine development is changing. Personalised medicine is making huge waves in the industry, and from this we have seen the rise of therapeutic vaccines for diseases such as cancer. Alongside this, the Ebola crisis has caused all stakeholders to re-evaluate the processes for research and manufacture of vaccines to ensure that they can roll them out as …

Geographical risk of Dengue and clinical studies conducted by Sanofi Pasteur

Making Dengue the Next Vaccine-Preventable Disease

Each year, there are approximately 50 million Dengue infections and an estimated 500,000 individuals are hospitalized with Dengue haemorrhagic fever. There have been attempts to develop a Dengue vaccine since the 1940s, but due to the limited appreciation of its global disease burden and market value, the industry’s interest deteriorated in the 20th century.   In 2013, the WHO ranked …

Amongst the flurry of efforts to combat the West African Ebola outbreak, Johnson & Johnson is trying its hand at developing a vaccine

Johnson & Johnson To Fast Track Ebola Vaccine Trials

Amongst the flurry of efforts to combat the West African Ebola outbreak, Johnson & Johnson is trying its hand at developing a vaccine Johnson & Johnson can be counted amongst the ranks of yet another pharmaceutical company that has joined the race to develop an Ebola vaccine. Thus far, the most advanced vaccine candidate is Glaxo Smith Kline’s, which is the …

Polio Strain Resistant to Vaccine was Responsible for 2010 Congo Outbreak

A vaccine resistant mutation of the poliovirus was the cause of the major 2010 polio outbreak in DR Congo Research published in the scientific journal ‘Proceedings of the National Academy of Sciences‘ has shown that a mutated strain of the poliovirus was responsible for a 2010 outbreak in the Democratic Republic of Congo, which claimed 209 lives. It was initially …

New Vaccine Provides Greater Protection than BCG Against Both Tuberculosis and Leprosy

Research headed by UCLA has found that a variation of the BCG vaccine offers stronger protection against the diseases Both tuberculosis and leprosy often occur together, and leprosy usually only occurs in places where tuberculosis occurs. Most infants are vaccinated against the two diseases with the Bacille Calmette-Guerin vaccination, which has been used for over a century now. However this …